These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 35543733

  • 21. Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience.
    Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Butticè S, Salonia A, Briganti A, Damiano R.
    Urology; 2017 Aug; 106():139-145. PubMed ID: 28438628
    [Abstract] [Full Text] [Related]

  • 22. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study.
    Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, Scuderi S, Robesti D, Leni R, Samanes Gajate AM, Picchio M, Gianolli L, Brembilla G, De Cobelli F, van Oosterom MN, van Leeuwen FWB, Montorsi F, Briganti A.
    Eur Urol; 2022 Oct; 82(4):411-418. PubMed ID: 35879127
    [Abstract] [Full Text] [Related]

  • 23. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
    Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.
    Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
    [Abstract] [Full Text] [Related]

  • 24. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB, van Leeuwen PJ, Busstra MB, Brabander T, van der Poel HG, Donswijk ML, Vis AN, Emmett L, Stricker PD, Roobol MJ.
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [Abstract] [Full Text] [Related]

  • 25. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 26. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool.
    Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler W, Marra G, Stabile A, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Sierra JM, Porpiglia F, Picchio M, van den Bergh R, Shariat SF, Montorsi F, Briganti A.
    Eur Urol Oncol; 2023 Dec; 6(6):543-552. PubMed ID: 37270378
    [Abstract] [Full Text] [Related]

  • 27. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [Abstract] [Full Text] [Related]

  • 28. Development and external validation of a multivariable [68Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer.
    Muehlematter UJ, Schweiger L, Ferraro DA, Hermanns T, Maurer T, Heck MM, Rupp NJ, Eiber M, Rauscher I, Burger IA.
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3137-3146. PubMed ID: 37261472
    [Abstract] [Full Text] [Related]

  • 29. 18 F-prostate specific membrane antigen positron emission tomography/computerized tomography for lymph node staging in medium/high risk prostate cancer: A systematic review and meta-analysis.
    Lv Z, Song L, Wang M, Hou H, Li H, Wang X, Wang J, Wang J, Liu M.
    Chin Med J (Engl); 2024 Apr 20; 137(8):949-958. PubMed ID: 37690993
    [Abstract] [Full Text] [Related]

  • 30. Prospective comparison of 18F-PSMA-1007 PET/CT, whole-body MRI and CT in primary nodal staging of unfavourable intermediate- and high-risk prostate cancer.
    Malaspina S, Anttinen M, Taimen P, Jambor I, Sandell M, Rinta-Kiikka I, Kajander S, Schildt J, Saukko E, Noponen T, Saunavaara J, Dean PB, Sequeiros RB, Aronen HJ, Kemppainen J, Seppänen M, Boström PJ, Ettala O.
    Eur J Nucl Med Mol Imaging; 2021 Aug 20; 48(9):2951-2959. PubMed ID: 33715033
    [Abstract] [Full Text] [Related]

  • 31. Accuracy of 68Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer.
    Barbosa ÁRG, Amaral BS, Lourenço DB, Bianco B, Gushiken FA, Apezzato M, Silva JF, Cunha MLD, Filippi RZ, Baroni RH, Lemos GC, Carneiro A.
    Einstein (Sao Paulo); 2022 Aug 20; 20():eAO6599. PubMed ID: 35584444
    [Abstract] [Full Text] [Related]

  • 32. Assessing the accuracy of [18F]PSMA-1007 PET/CT for primary staging of lymph node metastases in intermediate- and high-risk prostate cancer patients.
    Ingvar J, Hvittfeldt E, Trägårdh E, Simoulis A, Bjartell A.
    EJNMMI Res; 2022 Aug 09; 12(1):48. PubMed ID: 35943665
    [Abstract] [Full Text] [Related]

  • 33. Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer.
    van Kalmthout LWM, van Melick HHE, Lavalaye J, Meijer RP, Kooistra A, de Klerk JMH, Braat AJAT, Kaldeway HP, de Bruin PC, de Keizer B, Lam MGEH.
    J Urol; 2020 Mar 09; 203(3):537-545. PubMed ID: 31487220
    [Abstract] [Full Text] [Related]

  • 34. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug 09; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 35. Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.
    Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.
    J Transl Med; 2017 Nov 07; 15(1):230. PubMed ID: 29115970
    [Abstract] [Full Text] [Related]

  • 36. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
    Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM.
    Prostate Cancer Prostatic Dis; 2022 Mar 07; 25(1):65-70. PubMed ID: 34471231
    [Abstract] [Full Text] [Related]

  • 37. 99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.
    Yılmaz B, Şahin S, Ergül N, Çolakoğlu Y, Baytekin HF, Sökmen D, Tuğcu V, Taşçı Aİ, Çermik TF.
    Ann Nucl Med; 2022 Jul 07; 36(7):597-609. PubMed ID: 35426599
    [Abstract] [Full Text] [Related]

  • 38. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
    Hinsenveld FJ, Wit EMK, van Leeuwen PJ, Brouwer OR, Donswijk ML, Tillier CN, Vegt E, van Muilekom E, van Oosterom MN, van Leeuwen FWB, van der Poel HG.
    J Nucl Med; 2020 Apr 07; 61(4):540-545. PubMed ID: 31562222
    [Abstract] [Full Text] [Related]

  • 39. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
    Kim SJ, Lee SW, Ha HK.
    Urol Int; 2019 Apr 07; 102(1):27-36. PubMed ID: 30269140
    [Abstract] [Full Text] [Related]

  • 40. Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.
    Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.
    BJU Int; 2019 Sep 07; 124(3):401-407. PubMed ID: 31141284
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.